| abstract |
In one aspect, the invention provides an HCV therapy comprising an HCV protease inhibitor (such as ABT-450 (Compound 1) or danoprevir) and a cytochrome P450 monooxygenase inhibitor (such as ritonavir or cobicistat). Featuring HCV therapy that improves the pharmacokinetics of the HCV protease inhibitor using ritonavir as a pharmacokinetic booster, including administering to patients in need thereof. HCV therapy does not require testing total cholesterol and triglyceride levels before and after treatment. |